C2N Diagnostics bags UK MHRA approval for PrecivityAD2 blood test, advancing Alzheimer’s diagnosis
C2N Diagnostics, LLC, a leader in advanced diagnostic solutions for neurodegenerative diseases, has obtained medical device certification from the United Kingdom’s Medicines and Healthcare products ... Read More
C2N’s PrecivityAD2 blood test improves Alzheimer’s diagnosis and clinical decision-making, study finds
A new study has demonstrated that healthcare providers who used the PrecivityAD2 blood biomarker test, developed by C2N Diagnostics, significantly improved their ability to assess ... Read More